Soma Vikas R, Cavusoglu Erdal, Vidhun Raghuraman, Frishman William H, Sharma Samin K
Department of Medicine, Bronx VA Medical Center, Bronx, New York, USA.
Heart Dis. 2002 Nov-Dec;4(6):372-9. doi: 10.1097/00132580-200211000-00006.
Contrast-associated nephropathy (CaN) has become a major cause of iatrogenic acute renal failure, especially with the increasing use of radiographic contrast media in both diagnostic and interventional procedures. CaN is the third most common cause of iatrogenic acute renal failure, and is associated with increased morbidity and in-hospital mortality. CaN typically presents as an acute rise in serum creatinine levels, usually within 48 hours after exposure to contrast media. Renal medullary ischemia secondary to contrast-induced vasoconstriction is now believed to be the most likely cause of CaN, although direct renal tubular cytotoxicity does appear to play a role. The occurrence of CaN is directly related to the number of coexisting clinical risk factors. Among the many risk factors, preexisting renal impairment, the presence of diabetes mellitus and the volume of the contrast agent administered are the most important. The most effective means of reducing the incidence of CaN is through prevention, by first identifying the risk factors and then attempting to correct for them before the administration of contrast material. Although the earliest and most well-tested preventive measure, namely intravenous hydration, continues to be the most effective way to prevent CaN, recent studies have provided many new preventive modalities. The growing use of these new agents, such as acetylcysteine, endothelin blockers, and most recently fenoldopam, has increased the options available for the prevention of CaN.
对比剂肾病(CaN)已成为医源性急性肾衰竭的主要原因,尤其是在诊断和介入操作中使用放射造影剂日益增多的情况下。CaN是医源性急性肾衰竭的第三大常见原因,与发病率和住院死亡率增加相关。CaN通常表现为血清肌酐水平急性升高,通常在接触造影剂后48小时内出现。尽管直接肾小管细胞毒性似乎确实起作用,但目前认为造影剂诱导的血管收缩继发的肾髓质缺血是CaN最可能的原因。CaN的发生与并存的临床危险因素数量直接相关。在众多危险因素中,既往存在的肾功能损害、糖尿病的存在以及造影剂的使用量最为重要。降低CaN发病率的最有效方法是预防,首先识别危险因素,然后在给予造影剂之前尝试纠正这些因素。尽管最早且经过充分测试的预防措施,即静脉补液,仍然是预防CaN的最有效方法,但最近的研究提供了许多新的预防方式。这些新药物,如乙酰半胱氨酸、内皮素阻滞剂以及最近的非诺多泮的使用日益增加,为预防CaN提供了更多选择。